Reseach and Markets: View Profiles of 65 Selected Companies That Either Develop Technologies for Drug Delivery to the Cardiovascular System or Products Using These Technologies

Oct 20, 2005, 01:00 ET from Research and Markets

    DUBLIN, Ireland, October 20 /PRNewswire/ -- Research and Markets
 ( has announced the addition
 of Cardiovascular Drug Delivery - Technologies, Markets and Companies to
 their offering.
     (Logo: )
     Drug delivery to the cardiovascular system is different from delivery to
 other systems because of the anatomy and physiology of the vascular system;
 it supplies blood and nutrients to all organs of the body. Drugs can be
 introduced into the vascular system for systemic effects or targeted to an
 organ via the regional blood supply. In addition to the usual formulations of
 drugs such as controlled release, devices are used as well. This report
 starts with an introduction to molecular cardiology and discusses its
 relationship to biotechnology and drug delivery systems.
     Drug delivery to the cardiovascular system is approached at three levels:
     (1) Routes of drug delivery;
     (2) Formulations; and finally
     (3) Applications to various diseases.
     Formulations for drug delivery to the cardiovascular system range from
 controlled release preparations to delivery of proteins and peptides. Cell
 and gene therapies, including antisense and RNA interference, are described
 in full chapters as they are the most innovative methods of delivery of
 therapeutics. Various methods of improving systemic administration of drugs
 for cardiovascular disorders are described including use of nanotechnology.
     Cell-selective targeted drug delivery has emerged as one of the most
 significant areas of biomedical engineering research, to optimize the
 therapeutic efficacy of a drug by strictly localizing its pharmacological
 activity to a pathophysiologically relevant tissue system. These concepts
 have been applied to targeted drug delivery to the cardiovascular system.
 Devices for drug delivery to the cardiovascular system are also described.
     Role of drug delivery in various cardiovascular disorders such as
 myocardial ischemia, hypertension and hypercholesterolemia is discussed. Some
 of the preparations and technologies are also applicable to peripheral
 arterial diseases. Controlled release systems are based on
 chronopharmacology, which deals with the effects of circadian biological
 rhythms on drug actions. A full chapter is devoted to drug-eluting stents as
 treatment for restenosis following stenting of coronary arteries. Fifteen
 companies are involved in drug-eluting stents.
     New cell-based therapeutic strategies are being developed in response to
 the shortcomings of available treatments for heart disease. Potential repair
 by cell grafting or mobilizing endogenous cells holds particular attraction
 in heart disease, where the meager capacity for cardiomyocyte proliferation
 likely contributes to the irreversibility of heart failure. Cell therapy
 approaches include attempts to reinitiate cardiomyocyte proliferation in the
 adult, conversion of fibroblasts to contractile myocytes, conversion of bone
 marrow stem cells into cardiomyocytes, and transplantation of myocytes or
 other cells into injured myocardium.
     Advances in molecular pathophysiology of cardiovascular diseases have
 brought gene therapy within the realm of possibility as a novel approach to
 treatment of these diseases. It is hoped that gene therapy will be less
 expensive and affordable because the techniques involved are simpler than
 those involved in cardiac bypass surgery, heart transplantation and stent
 implantation. Gene therapy would be a more physiologic approach to deliver
 vasoprotective molecules to the site of vascular lesion. Gene therapy is not
 only a sophisticated method of drug delivery; it may at time need drug
 delivery devices such as catheters for transfer of genes to various parts of
 the cardiovascular system.
     The cardiovascular drug delivery markets are estimated for the years 2005
 to 2015 on the basis of epidemiology and total markets for cardiovascular
 therapeutics. The estimates take into consideration the anticipated advances
 and availability of various technologies, particularly drug delivery devices
 in the future. Markets for drug-eluting stents are calculated separately.
 Role of drug delivery in developing cardiovascular markets is defined and
 unmet needs in cardiovascular drug delivery technologies are identified.
     Selected 65 companies that either develop technologies for drug delivery
 to the cardiovascular system or products using these technologies are
 profiled and 65 collaborations between companies are tabulated. The
 bibliography includes 120 selected references from recent literature on this
 topic. The report is supplemented with 26 tables and 5 figures
     For more information visit
     Laura Wood
     Senior Manager
     Research and Markets
     Fax: +353-1-4100-980

SOURCE Research and Markets